News >

Efforts Ongoing to Move Biosimilars Into Mainstream Cancer Care

Caroline Seymour
Published: Friday, Sep 06, 2019

Lee S. Schwartzberg,
MD

Lee S. Schwartzberg, MD
OneOncology is seeking to streamline the ease of delivering oncologic care and considers the commercial availability of biosimilars as an integral component in these efforts, explained newly appointed chief medical officer of the company, Lee S. Schwartzberg, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Community Practice Connections™: Show Me the Data™: Leveraging the Evidence to Optimize Applications of Biosimilars in CancerAug 30, 20201.5
Publication Bottom Border
Border Publication
x